[{"id":"f45473e2-7a95-4d17-95ba-c86a27ceffbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01244438","created_at":"2021-01-18T05:00:42.606Z","updated_at":"2024-07-02T16:36:19.600Z","phase":"Phase 2","brief_title":"Study of FP-1039 in Subjects With Endometrial Cancers","source_id_and_acronym":"NCT01244438","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR mutation • FGFR2 S252W","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR mutation • FGFR2 S252W"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FP-1039"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2021-12-13"}]